1. Home
  2. TUSK vs LPTX Comparison

TUSK vs LPTX Comparison

Compare TUSK & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TUSK
  • LPTX
  • Stock Information
  • Founded
  • TUSK 2014
  • LPTX 2011
  • Country
  • TUSK United States
  • LPTX United States
  • Employees
  • TUSK N/A
  • LPTX N/A
  • Industry
  • TUSK Oilfield Services/Equipment
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TUSK Energy
  • LPTX Health Care
  • Exchange
  • TUSK Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • TUSK 128.0M
  • LPTX 119.6M
  • IPO Year
  • TUSK 2016
  • LPTX N/A
  • Fundamental
  • Price
  • TUSK $2.63
  • LPTX $0.36
  • Analyst Decision
  • TUSK
  • LPTX Buy
  • Analyst Count
  • TUSK 0
  • LPTX 2
  • Target Price
  • TUSK N/A
  • LPTX $8.00
  • AVG Volume (30 Days)
  • TUSK 270.8K
  • LPTX 6.0M
  • Earning Date
  • TUSK 05-01-2025
  • LPTX 05-12-2025
  • Dividend Yield
  • TUSK N/A
  • LPTX N/A
  • EPS Growth
  • TUSK N/A
  • LPTX N/A
  • EPS
  • TUSK N/A
  • LPTX N/A
  • Revenue
  • TUSK $187,932,000.00
  • LPTX N/A
  • Revenue This Year
  • TUSK N/A
  • LPTX N/A
  • Revenue Next Year
  • TUSK $28.22
  • LPTX N/A
  • P/E Ratio
  • TUSK N/A
  • LPTX N/A
  • Revenue Growth
  • TUSK N/A
  • LPTX N/A
  • 52 Week Low
  • TUSK $1.68
  • LPTX $0.22
  • 52 Week High
  • TUSK $4.94
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • TUSK 61.95
  • LPTX 45.27
  • Support Level
  • TUSK $1.85
  • LPTX $0.22
  • Resistance Level
  • TUSK $2.64
  • LPTX $0.38
  • Average True Range (ATR)
  • TUSK 0.30
  • LPTX 0.05
  • MACD
  • TUSK 0.09
  • LPTX 0.02
  • Stochastic Oscillator
  • TUSK 89.62
  • LPTX 89.24

About TUSK Mammoth Energy Services Inc.

Mammoth Energy Services Inc is an integrated energy services company engaged in providing products and services to enable the exploration and development of North American onshore unconventional oil and natural gas reserves as well as the construction and repair of the electric grid for private utilities, public investor-owned utilities, and co-operative utilities through infrastructure services businesses. The company had three reportable segments, which includes well completion services (Well Completion), infrastructure services (Infrastructure) and natural sand proppant services (Sand). Key revenue is generated from Infrastructure which include electric utility infrastructure services to government-funded utilities, private utilities, public investor-owned utilities, etc.

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Share on Social Networks: